Cost-Effectiveness Analysis for Surgical, Angioplasty, or Medical Therapeutics for Coronary Artery Disease
Open Access
- 11 September 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 126 (11_suppl_1), S145-S150
- https://doi.org/10.1161/circulationaha.111.084442
Abstract
Background—: The Second Medicine, Angioplasty, or Surgery Study (MASS II) included patients with multivessel coronary artery disease and normal systolic ventricular function. Patients underwent coronary artery bypass graft surgery (CABG, n=203), percutaneous coronary intervention (PCI, n=205), or medical treatment alone (MT, n=203). This investigation compares the economic outcome at 5-year follow-up of the 3 therapeutic strategies. Methods and Results—: We analyzed cumulative costs during a 5-year follow-up period. To analyze the cost-effectiveness, adjustment was made on the cumulative costs for average event-free time and angina-free proportion. Respectively, for event-free survival and event plus angina-free survival, MT presented 3.79 quality-adjusted life-years and 2.07 quality-adjusted life-years; PCI presented 3.59 and 2.77 quality-adjusted life-years; and CABG demonstrated 4.4 and 2.81 quality-adjusted life-years. The event-free costs were $9071.00 for MT; $19 967.00 for PCI; and $18 263.00 for CABG. The paired comparison of the event-free costs showed that there was a significant difference favoring MT versus PCI ( P P P =0.01). The event-free plus angina-free costs were $16 553.00, $25 831.00, and $24 614.00, respectively. The paired comparison of the event-free plus angina-free costs showed that there was a significant difference favoring MT versus PCI ( P =0.04), and versus CABG ( P 0.05). Conclusions—: In the long-term economic analysis, for the prevention of a composite primary end point, MT was more cost effective than CABG, and CABG was more cost-effective than PCI. Clinical Trial Registration Information—: www.controlled-trials.com . Registration number: ISRCTN66068876.Keywords
This publication has 18 references indexed in Scilit:
- Economic Outcomes of Treatment Strategies for Type 2 Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes TrialCirculation, 2009
- Interpreting the Results of Cost-Effectiveness StudiesJournal of the American College of Cardiology, 2008
- Custos comparativos entre a revascularização miocárdica com e sem circulação extracorpóreaArquivos Brasileiros de Cardiologia, 2008
- Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary PatientsCirculation: Cardiovascular Quality and Outcomes, 2008
- Five-Year Follow-Up of the Medicine, Angioplasty, or Surgery Study (MASS II)Circulation, 2007
- Cost-effectiveness as an outcome in randomized clinical trialsClinical Trials, 2006
- Bias in published cost effectiveness studies: systematic reviewBMJ, 2006
- Relative Cost Comparison of Treatments for Coronary Artery Disease: The First Year Follow-Up of MASS II StudyCirculation, 2003
- Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel DiseaseNew England Journal of Medicine, 2001
- The ARTS (Arterial Revascularization Therapies Study): Background, goals and methodsInternational Journal of Cardiovascular Interventions, 1999